Drug Channels Institute Launches Six eLearning Modules on Pharmaceutical Economics.

Drug Channels Institute (DCI) has launched a suite of six eLearning modules designed to provide pharmaceutical professionals with insights into the economic forces shaping the industry. These modules aim to deliver up-to-date training on drug distribution, reimbursement, and pricing, covering key aspects such as fund flows, pharmacy economics, the business of specialty pharmacy, provider-administered drugs, pharmacy benefit managers (PBMs), and pharmaceutical wholesalers. The modules are intended for use by sales teams, market access groups, and any professional seeking to enhance their understanding of pharmaceutical economics. Each module incorporates interactive graphics, expert narration, and references to DCI reports. The content covers financial and product flows within the pharmaceutical distribution channel, explaining how money and medicines move between manufacturers, wholesalers, pharmacies, PBMs, and payers. Modules delve into the revenue generation and cost management strategies of retail, mail, and specialty pharmacies. They further explore the distribution, insurance coverage, and value-added services associated with specialty drugs, as well as the dynamics of provider-administered drugs, including buy-and-bill systems and ASP reimbursement. PBM operations, revenue streams, and interactions with manufacturers, payers, and pharmacies are also examined. Finally, the modules provide insights into the operations, profit generation, and services of pharmaceutical wholesalers, differentiating between full-line wholesalers and specialty distributors. The eLearning modules are available via site-wide license for organizational access, and DCI also offers licenses to its secure hosted learning environment. Individual licenses are not currently available.

Newsflash | Powered by GeneOnline AI
Date: April 15, 2025

Related posts:

Commerce Department Launches Section 232 Investigation into Pharmaceutical Imports’ Impact on National Security Research: Drug Pricing Models Key to Pharma Success; Value Demonstration is Crucial Beyond Patent Expiration Five Key Considerations Impact Pharmaceutical Company Valuation 75% of Generic Drug Applications Delayed by Freedom to Operate Issues: Stability Testing Strategies Highlighted

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後